Gain Therapeutics (GANX) Income from Continuing Operations (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Income from Continuing Operations of 5608732.0 for Q1 2026, down 23.81% year-over-year from 7361650.07 in Q1 2025, and down 1589.58% quarter-over-quarter from 376531.0 in Q4 2025.
Gain Therapeutics (GANX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Gain Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 5608732.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 23.81% year-over-year to 5608732.0; the TTM figure through Mar 2026 stood at 16325373.0 (up 21.99% YoY), while the FY2025 annual figure was 15246985.0, up 25.3% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 5608732.0, down from 376531.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 12667235.0 in Q4 2022, with the low at 8143078.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 4718263.0 (2023), against an average of 3768983.06.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations soared 493.4% in 2022, then sank 139.58% in 2023.
- Gain Therapeutics' Income from Continuing Operations stood at 12667235.0 in 2022, then slumped by 139.58% to 5013419.0 in 2023, then advanced by 24.84% to 3768304.0 in 2024, then soared by 109.99% to 376531.0 in 2025, then plunged by 1589.58% to 5608732.0 in 2026.
- Business Quant data shows GANX's Income from Continuing Operations at 5608732.0 in Q1 2026, 376531.0 in Q4 2025, and 5284085.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | -4.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.68 Mn |
| Mar 31, 2026 | -5.61 Mn |
| Dec 31, 2025 | 376,531.00 |
| Sep 30, 2025 | -5.28 Mn |
| Jun 30, 2025 | -5.81 Mn |
| Mar 31, 2025 | -4.53 Mn |
| Dec 31, 2024 | -3.77 Mn |
| Sep 30, 2024 | -4.49 Mn |
| Jun 30, 2024 | -8.14 Mn |
| Mar 31, 2024 | -4.01 Mn |
| Dec 31, 2023 | -5.01 Mn |
| Sep 30, 2023 | -4.72 Mn |
| Jun 30, 2023 | -7.69 Mn |
| Mar 31, 2023 | -5.14 Mn |
| Dec 31, 2022 | 12.67 Mn |
| Sep 30, 2022 | -4.56 Mn |
| Jun 30, 2022 | -5.09 Mn |
| Mar 31, 2022 | -3.27 Mn |
| Dec 31, 2021 | -3.22 Mn |
| Sep 30, 2021 | -4.66 Mn |